Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces Changes to its Board of Directors
- Resignation of Anthony Vernon and Appointment of Elisabeth Sandoval-Little - MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 5, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that
View HTML
Toggle Summary Intersect ENT Announces Closing of its Initial Public Offering
MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its initial public offering of 5,750,000 shares of
View HTML
Toggle Summary Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant
Approval Establishes New S Code for PROPEL to Facilitate Specific Coding & Payment MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 19, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that
View HTML
Toggle Summary Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis
Toggle Summary Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants
Toggle Summary Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, announced that the Company has changed the date of its previously scheduled first quarter 2021 financial
View HTML
Toggle Summary Intersect ENT Announces Enrollment of First Patient In Phase III Study of In-Office Treatment for Recurrent Chronic Sinusitis
Toggle Summary Intersect ENT Announces Executive Team Appointments
Christine Kowalski Joins as Chief Operations Officer; Susan Stimson Named Chief Strategy Officer MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 29, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today
View HTML
Toggle Summary Intersect ENT Announces Exercise of Underwriters' Option and the Closing of Its Public Offering
Underwriters Exercise Option for 537,300 Shares of Common Stock, Increasing Total Aggregate Proceeds to Approximately $103.0 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and
View HTML
Toggle Summary Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® Mini Sinus Implant